Article

African-American men have poorer survival rates after PCa treatment

African-American men tend to have poorer overall survival rates than Caucasian men after being treated for localized prostate cancer, a new study shows.

Related Videos
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
PSMA PET and treatment intensification in mHSPC
Mark Edney, MD, highlights pending telehealth legislation
Mark Edney, MD, highlights pending telehealth legislation
The Future of RAD-ENZ Combination Therapy
The Future of RAD-ENZ Combination Therapy
TAR-200 Clinical Development Program in NMIBC
TAR-200 Clinical Development Program in NMIBC
TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)
TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)
Applying Results From PEACE-3 to Your Patient Population
Applying Results From PEACE-3 to Your Patient Population
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
The importance of PSADT in high-risk, biochemically recurrent prostate cancer
Christina Ching, MD, on overcoming barriers to follow-up after pediatric stone surgery
Christina Ching, MD, on overcoming barriers to follow-up after pediatric stone surgery
Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
Helen L. Bernie, DO, MPH, answers a question during a Zoom video interview
Helen L. Bernie, DO, MPH, on the FDA’s labeling changes for testosterone products
Related Content
Radioligand therapy shows promising safety in patients with mCRPC
March 13th 2025

Radioligand therapy shows promising safety in patients with mCRPC

Hannah Clarke
The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Novel drug delivery approach shows promise for UTI
March 12th 2025

Novel drug delivery approach shows promise for UTI

Hannah Clarke
The method involves local delivery of the antibiotic gentamicin directly into the bladder tissue.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome
March 11th 2025

Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome

Hannah Clarke
"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.
Phase 3 trial launches ArteraAI Prostate Test for treatment selection
March 11th 2025

Phase 3 trial launches ArteraAI Prostate Test for treatment selection

Hannah Clarke
The goal of the trial is to improve quality of life by identifying patients who can safely reduce or avoid treatment with hormone therapy.
© 2025 MJH Life Sciences

All rights reserved.